Ludwig Merker

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Simon Heller, John B. Buse, Miles Fisher et al. · The Lancet · 2012 · 401 citations

Medicine, Endocrinology, Pharmacology +15

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker et al. · Diabetes Care · 2014 · 393 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker et al. · Diabetes Care · 2013 · 375 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

Michael Roden, Ludwig Merker, Anita Vedel Christiansen et al. · Cardiovascular Diabetology · 2015 · 134 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

Christopher S. Kovács, Veeraswamy Seshiah, Ludwig Merker et al. · Clinical Therapeutics · 2015 · 111 citations

Medicine, Pharmacology, Pharmacotherapy +14